← Leaderboards
Christian Hinrichs
Division Of Basic Sciences - Nci
$2,975,460
Attributed
$4,023,956
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$4,023,956 · 3
By mechanism
R00$2,350,290 · 1
U01$1,269,979 · 1
R21$403,687 · 1
Top collaborators
- Jian Cao2 shared
- Shin-Heng Chiou2 shared
- James L. Gulley2 shared
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Other Rising Stars on “Malignant Neoplasms”
- David Annett · Information Management Services, Inc.$35,571,865
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Jon White · Midwest Research Institute$17,594,074
- Carolina Porras · Fundacion Inciensa$10,814,023
- Alanna Maguire · Mayo Clinic Rochester$9,942,431
- Hill Georgette · Integrated Laboratory Systems, Llc$8,700,000
Research focus
Malignant NeoplasmsT-LymphocyteResponseTumorClinical TrialsHuman PapillomavirusT-Cell ReceptorT Cell TherapyGenesT-Cell Receptor GenesMediatingAdoptive TransferAnusVulvaOropharyngealVaginaCancer TherapyTumor-Infiltrating LymphocytesEngineered T CellsMalignant Neoplasm Of Cervix UteriIn VivoNext GenerationImmunotherapyInnovation
Grant awards (22)
The Landscape of Tumor intrinsic Genetic Resistance to T cell Therapy$783,430
R00 · FY2025 · CA · contact PI
E7 TCR-T cell therapy for HPV-associated cancers$627,893
U01 · FY2025 · CA · contact PI
Developing TCR-T cell therapy in renal cell carcinoma$183,494
R21 · FY2025 · CA
The Landscape of Tumor intrinsic Genetic Resistance to T cell Therapy$783,430
R00 · FY2024 · CA · contact PI
E7 TCR-T cell therapy for HPV-associated cancers$642,086
U01 · FY2024 · CA · contact PI
Developing TCR-T cell therapy in renal cell carcinoma$220,193
R21 · FY2024 · CA
The Landscape of Tumor intrinsic Genetic Resistance to T cell Therapy$783,430
R00 · FY2023 · CA · contact PI
T-cell receptor gene therapy for cancer$2,022,756
ZIA · FY2021 · CA · contact PI
T-cell receptor gene therapy for cancer$3,427,390
ZIA · FY2020 · CA · contact PI
T-Cell Receptor Gene Therapy for Human Cancers-Cures$2,287,338
ZIA · FY2020 · CA · contact PI
T-cell receptor gene therapy for cancer$2,858,504
ZIA · FY2019 · CA · contact PI
T-cell receptor gene therapy for cancer$2,008,917
ZIA · FY2018 · CA · contact PI
T-cell receptor gene therapy for human papillomavirus-positive cancers$934,220
ZIA · FY2017 · CA · contact PI
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers$934,220
ZIA · FY2017 · CA · contact PI
T-cell receptor gene therapy for human papillomavirus-positive cancers$1,056,174
ZIA · FY2016 · CA · contact PI
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers$1,056,174
ZIA · FY2016 · CA · contact PI
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers$664,454
ZIA · FY2015 · CA · contact PI
T-cell receptor gene therapy for human papillomavirus-positive cancers$664,454
ZIA · FY2015 · CA · contact PI
T-cell receptor gene therapy for human papillomavirus-positive cancers$282,613
ZIA · FY2014 · CA · contact PI
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers$282,613
ZIA · FY2014 · CA · contact PI
T-cell receptor gene therapy for human papillomavirus-positive cancers$227,059
ZIA · FY2013 · CA · contact PI
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers$227,059
ZIA · FY2013 · CA · contact PI